PRLD

Prelude Therapeutics Incorporated · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-10

Figures on this page computed 2026-11-08 12:48 UTC

Last close

4.08USD

Market data, 2026-11-04

PRLD: weekly closes from 1.19 on 2025-11-07 to 4.08 on 2026-11-04, a move of +242.9%. Prices in USD.

Weekly closes, 2025-11-07 to 2026-11-04

Over that span: +242.9%

Except where said otherwise: 10-K for 2025, filed 2026-03-10

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-10
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-11
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-11
The filing itself
-819.6%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
-464.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
0.26Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-11
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.15 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.27x

1.18x

0.85x

1.90x

0.36x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-10

Sales1.27x
Its own average over 2 years, 9.6M.
Profit1.18x
Its own average over 8 years, -84.4M.
Free cash flow0.85x
Its own average over 8 years, -66.2M.
Debt1.90x
Its own average over 6 years, 9.4M.
Price0.36x
Its own average over 7 years, 11. Market data, 2026-11-04

Debt is furthest from its own average, at 1.90 times.

The filed years, as a table

Each line is 100 at 2018-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2018-12-31	n/a	100.0
2021-12-31	n/a	2,921.2
2022-12-31	n/a	3,005.1
2023-12-31	n/a	3,828.8
2024-12-31	100.0	4,808.8
2025-12-31	173.4	4,881.8

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-099428
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-099428
Reported in: USD

The filing itself

Figures behind the shape

Growth

21.8%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income21.8%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

-145.0%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-11
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-11
The filing itself
Return on equity-145.0%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-11
The filing itself
Return on assets-70.4%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-11
The filing itself

Margins

-861.3%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross marginn/a
We do not hold this figure for this company, so there is nothing to place.
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
Operating margin-861.3%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
Net margin-819.6%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
Free cash flow margin-464.3%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself

Price

4.0x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-10
The filing itself
Price to book4.0x10-Q for 2025, filed 2026-08-11
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-343475
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-11
- computed
- 10-K for 2025, filed 2026-03-10
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-11
- 10-K for 2025, filed 2026-03-10
The filing itself
Price to sales ratio22.8x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself

Safety

0.26

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity0.26
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-Q for 2025, filed 2026-08-11
The filing itself
Current ratio1.9910-Q for 2025, filed 2026-08-11
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001193125-26-343475
Reported in
USD
- 10-Q for 2025, filed 2026-08-11
- 10-Q for 2025, filed 2026-08-11
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
Altman Z-Score-6.39
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-10
- Computed from the 10-K for 2025, filed 2026-03-10
- Computed from the 10-K for 2025, filed 2026-03-10
- Computed from the 10-K for 2025, filed 2026-03-10
- Computed from the 10-K for 2025, filed 2026-03-10

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001193125-26-099428
Reported in
USD
- 10-K for 2025, filed 2026-03-10
- Computed from the 10-K for 2025, filed 2026-03-10
- 10-K for 2025, filed 2026-03-10
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.